Key Drivers
- Strong Liquidity
- Margin Improvement
- Ongoing Cash Burn
AIAI Summary
BFLY is evolving from a “good hardware, weak economics” story into a potential AI/platform turnaround, but the stock only becomes investable if FDA-cleared products and clinical validation quickly translate into recurring, higher-margin revenue before ongoing cash burn and dilution pressure erase the upside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Margin Improvement
- •Ongoing Cash Burn
BFLY shows solid liquidity and improved operating margins/cost control, but it is still loss-making, cash-burning, and looks expensive versus fundamentals.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support holding
- •Failed rebound
BFLY remains in a last month downtrend with lower highs/lower lows; support near $3.80 is holding for now, but failed rebounds and fading momentum keep sellers in control.
Sharp rebound from the low $4s to $5.40 on 2026-05-01 quickly faded
Sentiment & News
Key News Insights:
- •Better Q1 loss
- •CMO appointment
- •Investor outreach
Butterfly Network posted better-than-expected Q1 results while adding key medical and board leadership and increasing investor outreach, signaling improving execution and stronger governance.
These updates are modestly positive for the stock, as they point to improving operational discipline and credibility, though sustained execution will be needed to drive a rerating
Similar Companies in Healthcare
Other companies in the same sector with AI ratings